NCT04489732View on ClinicalTrials.gov

MSC in Patients With Xerostomia Post XRT in Head and Neck Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

February 18, 2022

Primary Completion Date

November 22, 2022

Study Completion Date

May 31, 2026

Conditions
Xerostomia Following Radiotherapy
Interventions
BIOLOGICAL

Autologous bone-marrow derived, interferon gamma stimulated mesenchymal stromal cells

"Single dose, starting at~* Dose Level 0: 10 (8-12) x 10\^6 injected into one submandibular gland on Day 1~Sub-study for second injection after primary objectives met, 10 (8 - 12) x 10\^6 MSCs will be offered for injection into each participant's contralateral submandibular gland"

Trial Locations (1)

53705

University of Wisconsin, Madison

All Listed Sponsors
collaborator

National Institute of Dental and Craniofacial Research (NIDCR)

NIH

lead

University of Wisconsin, Madison

OTHER